Medicenna Therapeutics stock highlights pipeline milestones after H.C. Wainwright talk

Published on 09/17/2026 at 17:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medicenna Therapeutics stock trades around USD 0.29 as of September 16, 2026, more than 80 percent below its 52-week high, while management points to multiple clinical catalysts ahead. The company sees bizaxofusp doubling survival in recurrent glioblastoma versus an external control and expects key MDNA11 data in the fourth quarter.

MDNA, CA5846991016, Illustration mit AI erstellt.

Medicenna Therapeutics stock (ISIN CA5846991016) is trading at about USD 0.29 as of September 16, 2026, leaving the small-cap immunotherapy company valued at roughly CAD 40 million and more than 80 percent below its 52-week high of USD 1.41, according to Investing.com on September 16, 2026.

Conference sets near-term catalyst calendar

On September 16, 2026, Medicenna used its slot at the H.C. Wainwright 28th Annual Global Investment Conference to lay out a dense pipeline and a series of clinical and regulatory milestones it expects over the next three to six months, as confirmed by the company’s event listing on its investor-relations site and the detailed presentation transcript from Medicenna Therapeutics and Investing.com.

According to Investing.com, management told investors it expects multiple “value-driving events” between roughly late 2026 and early 2027, including top-line data from the ABILITY-1 phase I/II trial of MDNA11, interim neoadjuvant data from an 80-patient Italian study, updated bizaxofusp results to be presented orally at a major conference, and completion of IND-enabling studies for MDNA113 followed by an IND filing.

The company’s own events calendar shows the H.C. Wainwright appearance scheduled for September 16, 2026 at 12:00 p.m. Eastern Time, underlining that these catalysts were communicated as part of a broader effort to reset investor expectations around the MDNA11 IL-2 superagonist, bizaxofusp for recurrent glioblastoma, and the MDNA113 bispecific program, as reflected on Medicenna Therapeutics.

Bizaxofusp shows doubled survival in recurrent glioblastoma

One of the most striking figures in the presentation was the median survival data for bizaxofusp, Medicenna’s IL-4 engineered Superkine fused to a cytotoxic payload and tested in recurrent non-resectable glioblastoma, where a phase IIb study showed median survival of about 13.5 months versus 7.2 months in a matched external control arm, according to Investing.com.

Management framed that survival gain as a roughly 100 percent improvement for end-stage patients who typically see 6 to 7 months median survival with currently available therapies in this setting, highlighting that the trial used a single intratumoral dose of bizaxofusp yet still achieved nearly 14 months median survival, while the external control arm was built using FDA guidance and matched on 10 prognostic factors such as tumor size, location and Karnofsky performance status per Investing.com.

Bizaxofusp, also known as MDNA55, has been granted Fast Track and Orphan Drug designations by the United States Food and Drug Administration, and Medicenna said the phase III registration trial design is already aligned with the regulator, with plans to allow multiple treatments rather than the single dose used in phase IIb and to move toward a phase III start next year subject to partnering, according to Investing.com.

For investors, the context matters: the recurrent glioblastoma market is estimated at about CAD 800 million, while broader central nervous system tumor indications such as newly diagnosed glioblastoma, metastatic breast, colon and renal cancers, and pediatric tumors could expand the opportunity to roughly CAD 4 billion, and Medicenna stressed that IL-4 receptor overexpression in these tumors and on myeloid-derived suppressor cells gives bizaxofusp a dual role in purging immunosuppressive cells and inducing immunogenic cell death, as described in detail by Investing.com.

MDNA11 aims at checkpoint non-responders

Alongside bizaxofusp, Medicenna positioned MDNA11, its long-acting IL-2 superagonist, as a potential best-in-class candidate for checkpoint inhibitor non-responders, noting that the global checkpoint inhibitor market generates about USD 60 billion in annual sales but benefits only around 30 percent of patients, leaving roughly two-thirds without durable benefit, according to the H.C. Wainwright transcript on Investing.com.

MDNA11 is being evaluated in the ABILITY-1 phase I/II study, which had enrolled about 150 patients across multiple tumor types and was expected to complete enrollment by the end of September 2026, with four expansion cohorts focused on melanoma, gastrointestinal tumors, endometrial cancer and MSI-high tumors and response rates in previously checkpoint inhibitor-failed patients reported in the 30 to 40 percent range, either as monotherapy or in combination with Keytruda, according to Investing.com.

Management explained that MDNA11 differs from earlier IL-2 derivatives in three key ways: it includes two mutations that abolish alpha-domain binding to reduce regulatory T-cell stimulation and improve safety, it dramatically increases beta-receptor binding to boost effector and memory T cells and natural killer cells, and it is fused to human albumin to extend half-life and drive accumulation in tumor-draining lymph nodes, which serve as training grounds for antitumor immune responses, as outlined by Investing.com.

Beyond ABILITY-1, an externally funded 80-patient neoadjuvant study in Italy is comparing MDNA11 head-to-head against the combination of Opdivo and Yervoy, with interim data expected in the fourth quarter of 2026, and Medicenna plans an end-of-phase I meeting with the FDA following the ABILITY-1 oral presentation to discuss potential phase II registration trials and an accelerated approval pathway for one or more tumor cohorts, according to the same transcript on Investing.com.

MDNA113 and earlier programs broaden the platform

Medicenna also highlighted MDNA113 as a first-in-class targeted NTPDase1 IL-2 bispecific designed to combine a commercially proven anti-PD-1 backbone with its beta-enhanced IL-2 and a tumor-site targeting component directed at IL-13 receptor alpha-2, a marker the company says is overexpressed in many solid tumors and associated with more aggressive disease, with about 2 million cancer patients diagnosed each year expressing this target, according to Investing.com.

Lower in the pipeline, MDNA209 is positioned as an IL-2 super antagonist aimed at autoimmune disease, while MDNA413 targets IL-4 and IL-13 blockade and is described as a potential improved version of Dupixent for inflammatory conditions, and Medicenna said it is engaged in partnering discussions around these earlier-stage assets, pointing to recent multi-billion-dollar transactions in the autoimmune and immunology space as comparables, according to Investing.com.

For shareholders, that broader platform matters because it makes the company less dependent on a single program’s outcome: bizaxofusp is already phase III-ready with an FDA-aligned design in recurrent glioblastoma, MDNA11 is delivering single-agent and combination activity in checkpoint-experienced tumors, and MDNA113 is being positioned to address aggressive IL-13 receptor alpha-2-positive cancers where the company argues standard anti-PD-1 approaches have limited impact, as per the detailed explanation on Investing.com.

Stock valuation, analyst targets and funding runway

Despite the pipeline, Medicenna emphasized that it remains a small-cap, Toronto-listed company with about 92 million shares outstanding and a market capitalization of roughly CAD 40 million, and insiders hold around 20 percent of the shares, which management highlighted as a sign of alignment with shareholder interests, according to Investing.com.

The transcript notes that the stock trades around USD 0.29, has fallen roughly 47 percent over the past six months, and stands more than 80 percent below its 52-week high of USD 1.41, underscoring how far the shares have slipped relative to their recent peak even as management argues the current valuation looks low versus recent immunotherapy transaction values in the bispecific and cytokine space, per Investing.com.

According to the same presentation, analysts covering Medicenna have price targets that range from USD 1.15 to USD 2.87, implying that consensus views sit several times above the current share price level, and the company said it is followed by four analysts, two based in Canada and two in the United States, while InvestingPro’s fair-value analysis characterizes the stock as fairly valued at current levels, as cited by Investing.com.

On the funding side, Medicenna stated that its current cash position plus additional funds expected through a sharing agreement provide operational runway into the second quarter of 2024, and analysts forecast positive earnings per share of USD 0.45 for fiscal 2027, which management cited as a potential future inflection point despite the company remaining unprofitable over the last twelve months, according to Investing.com.

Stock stays deeply below its 52-week high

With the shares at about USD 0.29 as of September 16, 2026 on their Toronto Stock Exchange listing and the 52-week high at USD 1.41, Medicenna Therapeutics stock is trading around one-fifth of its recent peak, emphasizing how much of the potential pipeline value investors have yet to price in relative to the survival gains reported for bizaxofusp and the early response rates for MDNA11.